Login to Your Account

Washington Roundup

CRS: Many Issues Could Trip Up PDUFA Reauthorization

By Mari Serebrov
Washington Editor

Wednesday, February 29, 2012
WASHINGTON – After months and months of negotiating the provisions of PDUFA V with the FDA, biopharma is holding its collective breath as the user fee agreement wends its way through the congressional process.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription